The ERBB network: At last, cancer therapy meets systems biology

Yosef Yarden; Gur Pines

doi:10.1038/nrc3309

The ERBB network: At last, cancer therapy meets systems biology

Yosef Yarden, Gur Pines

Department of Immunology and Regenerative Biology

Weizmann Institute of Science

Research output: Contribution to journal › Review article › peer-review

Abstract

Although it is broadly agreed that the improved treatment of patients with cancer will depend on a deeper molecular understanding of the underlying pathogenesis, only a few examples are already available. This Timeline article focuses on the ERBB (also known as HER) network of receptor tyrosine kinases (RTKs), which exemplifies how a constant dialogue between basic research and medical oncology can translate into both a sustained pipeline of novel drugs and ways to overcome acquired treatment resistance in patients. We track the key early discoveries that linked this RTK family to oncogenesis, the course of pioneering clinical research and their merger into a systems-biology framework that is likely to inspire further generations of effective therapeutic strategies.

Original language	English
Pages (from-to)	553-563
Number of pages	11
Journal	Nature Reviews Cancer
Volume	12
Issue number	8
DOIs	https://doi.org/10.1038/nrc3309
State	Published - Aug 2012

All Science Journal Classification (ASJC) codes

Oncology
Cancer Research

Access to Document

10.1038/nrc3309

Cite this

@article{0672b56b1c8f493a83a15d408ef97321,

title = "The ERBB network: At last, cancer therapy meets systems biology",

abstract = "Although it is broadly agreed that the improved treatment of patients with cancer will depend on a deeper molecular understanding of the underlying pathogenesis, only a few examples are already available. This Timeline article focuses on the ERBB (also known as HER) network of receptor tyrosine kinases (RTKs), which exemplifies how a constant dialogue between basic research and medical oncology can translate into both a sustained pipeline of novel drugs and ways to overcome acquired treatment resistance in patients. We track the key early discoveries that linked this RTK family to oncogenesis, the course of pioneering clinical research and their merger into a systems-biology framework that is likely to inspire further generations of effective therapeutic strategies.",

author = "Yosef Yarden and Gur Pines",

note = "US National Cancer Institute; European Research Council; European Commission; German-Israeli Project Cooperation (DIP); Israel Cancer Research Fund; Dr. Miriam and Sheldon G. Adelson Medical Research FoundationThe authors would like to thank M. Eisenstein, M. Feldman, Y. Mosesson, S. Lavi, W. Koestller and G. Tarcic for their help. They apologize to those colleagues whose work is not cited owing to space limitations. The authors' research is funded by the US National Cancer Institute, the European Research Council, the Seventh Framework Program of the European Commission, the German-Israeli Project Cooperation (DIP), the Israel Cancer Research Fund and the Dr. Miriam and Sheldon G. Adelson Medical Research Foundation. Y.Y. is the incumbent of the Harold and Zelda Goldenberg Professorial Chair.",

year = "2012",

month = aug,

doi = "10.1038/nrc3309",

language = "الإنجليزيّة",

volume = "12",

pages = "553--563",

journal = "Nature Reviews Cancer",

issn = "1474-175X",

publisher = "Nature Publishing Group",

number = "8",

}

TY - JOUR

T1 - The ERBB network

T2 - At last, cancer therapy meets systems biology

AU - Yarden, Yosef

AU - Pines, Gur

N1 - US National Cancer Institute; European Research Council; European Commission; German-Israeli Project Cooperation (DIP); Israel Cancer Research Fund; Dr. Miriam and Sheldon G. Adelson Medical Research FoundationThe authors would like to thank M. Eisenstein, M. Feldman, Y. Mosesson, S. Lavi, W. Koestller and G. Tarcic for their help. They apologize to those colleagues whose work is not cited owing to space limitations. The authors' research is funded by the US National Cancer Institute, the European Research Council, the Seventh Framework Program of the European Commission, the German-Israeli Project Cooperation (DIP), the Israel Cancer Research Fund and the Dr. Miriam and Sheldon G. Adelson Medical Research Foundation. Y.Y. is the incumbent of the Harold and Zelda Goldenberg Professorial Chair.

PY - 2012/8

Y1 - 2012/8

N2 - Although it is broadly agreed that the improved treatment of patients with cancer will depend on a deeper molecular understanding of the underlying pathogenesis, only a few examples are already available. This Timeline article focuses on the ERBB (also known as HER) network of receptor tyrosine kinases (RTKs), which exemplifies how a constant dialogue between basic research and medical oncology can translate into both a sustained pipeline of novel drugs and ways to overcome acquired treatment resistance in patients. We track the key early discoveries that linked this RTK family to oncogenesis, the course of pioneering clinical research and their merger into a systems-biology framework that is likely to inspire further generations of effective therapeutic strategies.

AB - Although it is broadly agreed that the improved treatment of patients with cancer will depend on a deeper molecular understanding of the underlying pathogenesis, only a few examples are already available. This Timeline article focuses on the ERBB (also known as HER) network of receptor tyrosine kinases (RTKs), which exemplifies how a constant dialogue between basic research and medical oncology can translate into both a sustained pipeline of novel drugs and ways to overcome acquired treatment resistance in patients. We track the key early discoveries that linked this RTK family to oncogenesis, the course of pioneering clinical research and their merger into a systems-biology framework that is likely to inspire further generations of effective therapeutic strategies.

UR - http://www.scopus.com/inward/record.url?scp=84864367360&partnerID=8YFLogxK

U2 - 10.1038/nrc3309

DO - 10.1038/nrc3309

M3 - مقالة مرجعية

SN - 1474-175X

VL - 12

SP - 553

EP - 563

JO - Nature Reviews Cancer

JF - Nature Reviews Cancer

IS - 8

ER -

The ERBB network: At last, cancer therapy meets systems biology

Abstract

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this